SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-268317
Filing Date
2021-09-09
Accepted
2021-09-09 07:00:38
Documents
12
Period of Report
2021-09-07
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d213539d8k.htm   iXBRL 8-K 21883
  Complete submission text file 0001193125-21-268317.txt   147697

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA gmtx-20210907.xsd EX-101.SCH 2908
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE gmtx-20210907_lab.xml EX-101.LAB 18886
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE gmtx-20210907_pre.xml EX-101.PRE 11870
5 EXTRACTED XBRL INSTANCE DOCUMENT d213539d8k_htm.xml XML 3535
Mailing Address 300 ONE KENDALL SQUARE, 3RD FLOOR CAMBRIDGE MA 02139
Business Address 300 ONE KENDALL SQUARE, 3RD FLOOR CAMBRIDGE MA 02139 (617) 401-4400
Gemini Therapeutics, Inc. /DE (Filer) CIK: 0001816736 (see all company filings)

IRS No.: 851613057 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39438 | Film No.: 211243484
SIC: 2834 Pharmaceutical Preparations